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OBJECTIVE: To evaluate the effect of different concentrations of estrogen on the ovarian superficial epithelium in senile female 
rats. Design: Fifty female rats at 15 months of age and with irregular estrous cycles were selected and randomly divided into five 
experimental groups containing equal numbers of animals in each: GPROP, control group receiving vehicle only; GE0.05mg, group 
receiving conjugated equine estrogens (CEE) at a dose of 50 µg/kg; GE0.5mg, group receiving CEE at 500 µg/kg; GE1mg, group 
receiving CEE at 1 mg/kg; and GE2mg, receiving CEE at 2 mg/kg. The length of treatment was 21 days. After this period, the 
animals were anesthetized and the ovaries were fixed in 10% formaldehyde and processed for routine histology. Histomorphology 
was analyzed by light microscopy, and histomorphometrics were evaluated using the Imagelab program. 
RESULTS: In the GPROP and GE0.05mg groups, the superficial epithelium of the ovary had a simple cuboidal shape, and as the 
estrogen dose increased, the epithelium thickened, with pseudo-stratified or stratified epithelium appearing in the GE2mg group. 
The animals in the group given the highest estrogen dose (GE2mg) showed the thickest ovarian epithelium and the largest perim-
eter and surface area of the surface ovarian epithelium (P < 0.01). However, the difference in epithelium thickness between the 
GE0.5mg and GE1mg groups was only slight. 
CONCLUSION: Our data suggest that CEE at a dose of 2 mg/kg may induce marked proliferation of rat ovarian epithelium. 
KEYWORDS: Estrogens. Superficial epithelium. Ovary. Animal Model.
INTRODUCTION
Ovarian carcinoma has an extremely poor prognosis 
and is one of the leading causes of morbidity and mortality 
in women with cancer. In general, the diagnosis of ovarian 
cancer occurs when the clinico-surgical stage is already 
quite advanced; in fact, 70% of women diagnosed with this 
condition are in stage III or IV.1 Cancer recurs in about 75% 
of patients with advanced primary tumors, even after initial 
therapy.2 The prognosis for patients with recurring disease 
remains poor, with a 23% five-year survival rate overall and 
a 14% survival rate for stages III and IV.3 For these reasons, 
the molecular pathways involved in the progression of 
ovarian cancer are excellent candidates as targets for treating 
and even preventing the disease. 
The gonadotropic theory of ovarian cancer postulates that 
it develops when the hypophysial gonadotropins (luteinizing 
hormone [LH] and follicle-stimulating hormone [FSH]) 
stimulate excessive growth of ovarian tissue.4 Pregnancy 
and the use of oral contraceptives containing progestagens 
suppress the release of gonadotropins, and may protect 
against development of ovarian cancer, particularly cancer 
of the ovarian superficial epithelium.5 Thus, it is possible 
that when ovarian cancer arises due to the superficial 
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epithelium of the ovary, it may be the result of excessive 
hormonal stimulation of the epithelial cells either on the 
surface of the ovary or within inclusion cysts. In addition, it 
is possible that excessive gonadotropin secretion mediates 
the growth stimulation. Post-menopausal women and women 
in menopausal transition have high levels of circulating 
gonadotropins, and patients with polycystic ovary syndrome 
have persistently elevated levels of luteinizing hormone. 
These two situations of increased gonadotropins may be risk 
factors for the development of ovarian cancer. 6, 7 Another 
hypothesis regarding ovarian cancer development is that 
increased risk may be associated with incessant ovulation, 
which involves chronic formation of stromal epithelial clefs 
and inclusion cysts following ovulation.5 In fact, repetitive 
cycles of epithelial insult and repair during ovulation 
promote genomic instability, which renders the superficial 
epithelial layer vulnerable to carcinogenesis.8 
Estrogen is a trophic hormone with anabolic properties, 
and it performs several functions in female biology.9 A 
significant reduction in estrogen levels in a woman may 
produce harmful effects such as an increased risk of 
osteoporosis and atrophy of the genital organs. Although 
hormone replacement therapy with exogenous estrogen 
may mitigate these changes, some women are susceptible 
to hormone-dependent neoplasias such as breast and 
uterine cancers.10-12 Some researchers believe that estrogen 
alone may play a role in the development of ovarian 
cancer, especially in malignancies related to the ovarian 
superficial epithelium.13 Epidemiological studies suggest 
that administration of estrogen to postmenopausal women 
may increase their risk of developing ovarian cancer.14 
Furthermore, estrogen levels in ovarian tissue are at least 100 
times higher than circulating estrogen levels and are even 
higher than those in ovarian follicular fluids. 
Elevated estrogen levels stimulate proliferation 
of ovarian superficial epithelial cells by activating 
cellular estrogen receptors. This promotes genetic 
instability because of the frequent rounds of DNA 
replication and recombination.15 The mitogenic effects 
of estrogen on ovarian cancer cells are a result of several 
signaling pathways, including regulation by growth 
factors and cytosines, 16 Bcl-2, 17 activation of the c-myc 
protooncogene,18 and TGF-α.19 Estrogen signaling activates 
interleukin-620 induces a rise in the circulating levels of 
growth factor. In a recent study using complementary 
DNA, several cancer-related genes regulated by estradiol 
were identified, including genes involved in cell cycle 
regulation (CCNB1), apoptosis (TRAP1), transcription 
(TFAP4), and cellular signaling (LCN2).21 Additionally, 
the estradiol metabolite 4-hydroxy estradiol enhances 
the expression of both inducible factor hypoxia-1α (HIF-
1α) and vascular endothelial growth factor (VEGF) in 
cancerous ovarian cells. This enhancement may play an 
important role in the progression and neoangiogenesis 
in tumors via phosphatidylinositol 3-kinase/Akt/FRAP 
signaling.22 Moreover, estrogen signaling may decrease 
GnRH and GnRHR expression, thus significantly reducing 
the ability of GnRH to inhibit the proliferation of ovarian 
cancer cells. 23 Estrogens also affect tumor progression by 
promoting invasion and metastasis through up-regulation 
of some genes involved in remodeling the cytoskeleton or 
extracellular matrix, such as fibulin-1C24 and fibernectin.21
In animals, continuous administration of estradiol 
(17beta-estradiol) leads to decreased ovulation and promotes 
proliferation of the ovarian superficial epithelium25 as well 
as the emergence of ovarian cysts. In rabbits, administration 
of 17beta-estradiol estrogen induces the formation of papilae 
on the ovarian superficial epithelium (OSE), which is 
histologically similar to the lesions found in low-malignancy 
serous neoplasia in human ovaries.26,27 The senile female rat 
does not undergo the hypoestrogenism secondary to ovarian 
failure that occurs in postmenopausal women, but when the 
rat is acyclic it maintains high levels of gonadotropins.28 
High levels of circulating gonadotropins in acyclic rats is 
a good model system for studying the effects of unopposed 
estrogens on the OSE.
Conjugated equine estrogens (CEE) are commonly used 
in postmenopausal hormone replacement therapy (HRT). 
These hormones are a combination of soluble estrogens 
from the urine of pregnant mares, and they include several 
biologically active components such as estrone, estradiol, 
and its respective sulphates, and sulphates of equine 
estrogens (equilin and equilenin). It should be pointed 
out that after absorption into the bloodstream, equilin and 
equilenin are converted into 17beta-dihydroequilin and 
17beta-dihydroequilenin, respectively. When conjugated 
estrogens are orally administered, part of the combination 
is absorbed as sulphate and the rest is hydrolyzed in 
the digestive tract and sulphated again after absorption. 
Nonconjugated estrogens may be interconverted in the liver 
and target tissues. These nonconjugated estrogens circulate 
bound to a globulin that transports sex hormones, whereas 
sulphated forms bind with high affinity to albumin. The 
pharmacokinetic parameters of conjugated equine estrogens 
are complex. When bound to albumin, the sulphated 
forms of estrone, equilin, equilenin, and their 17-dihydro 
metabolites are known to circulate at higher concentrations 
than nonconjugated estrogens. 
However, the effects of these hormones on the OSE 
have not been clarified. Results from epidemiological 
studies investigating the effects of HRT on carcinogenesis 
are contradictory. Several studies have been undertaken, 
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with some showing a significant increase in cancer risk,13, 29 
and others reporting no significant positive associations.30,31 
The inconsistencies among these studies may be due to 
differences in methodology or lack of control lack of control 
over conflicting factors.30, 32-35 For this reason, we decided 
to evaluate the carcinogenic effects of different doses of 
conjugated equine estrogens in senile female rats.
MATERIALS AND METHODS
Fifty rats (Rattus norvegicus albinus) of the EPM-1 
Wistar strain at 15 months of age were used. Average weight 
was 300 grams. The animals were supplied by the Center 
for the Development of Experimental Models in Medicine 
and Biology (CEDEME) of the Escola Paulista de Medicina 
at the Federal University of São Paulo (UNIFESP-EPM). 
The project design was approved by the ethics and research 
committee of the Federal University of São Paulo (protocol 
0944/03).
The animals were transported to the Histology and 
Structural Biology Biotery of the Morphology Department of 
UNIFESP-EPM, where they were confined to plastic cages 
45 x 30 x 15 cm in length, width, and height, respectively. 
The cages were lidded with metal grids. The rats were fed 
ad libitum, room temperature was maintained at 22°C and 
artificial lighting was maintained with fluorescent lamps (40 
W, daylight, Phillips). 
After adaption for new cages for one week, the rats 
were randomly divided into five study groups as follows: 
GPROP, which received 0.5 ml of propylene glycol (vehicle); 
GE50µg, which received a daily dose of CEE of 50 µg/kg; 
GE0.5mg, which received a daily CEE dose of 500 µg/kg; 
GE1mg, which received a daily CEE dose of 1 mg/kg; and 
GE2mg, which received a daily CEE dose of 2 mg/kg. 
The conjugated equine estrogens were diluted in 0.5 ml 
of propylene glycol and administered daily in the morning 
by gavage for 21 consecutive days. Gavage was performed 
with a standard metal tube supplied by the UNIFESP-EPM 
Pharmacology Department. 
Twenty-four hours after ingesting the final dose of CEE, 
the animals were anesthetized with xilazine (20 mg/kg) and 
ketamine (100 mg/kg) intraperitoneally. Upon laparotomy, 
the ovaries were removed and immediately immersed in a 
10% buffered formaldehyde solution for eight hours, sliced, 
and the pieces were dehydrated in increasing concentrations 
of ethyl alcohol, diaphanized in xylol, and impregnated with 
and embedded in paraffin. The histological cuts (4 µm) were 
stained with hematoxylin and eosine (HE). For morphological 
analysis, the cuts were observed with a light microscope under 
magnifications ranging from 100X to 400X. 
Morphometric studies were performed using a light 
microscope (Axiolab, Carl Zeiss) attached to an image 
capture system (AxionLab, Carl Zeiss). OSE measurements 
were made at four clock positions (12, 3, 6, and 9 o´clock) 
on serial sections using the AxionVision Morphometric 
Program (Carl Zeiss). A total of 40 consecutive observations 
were recorded for each animal (10 histological sections 
per rat). Also, the total evaluated width of the epithelium 
was approximately 5 mm per ovary (sums of all clock 
positions). The ovarian surface epithelial thickness, area, 
and perimeter were measured on profiles showing the 
whole epithelium from basement membrane to surface. The 
thickness was calculated from the average distances between 
the epithelium-stroma interface and the cell surface. The 
perimeter and area were measured by tracing the epithelium-
stroma interface (Fig. 1). The area (A) and perimeter (P) 
formulas are as follows: A = length x width, and P = (2 x 
length) + (2 x width). 
The sample size was calculated based on the central 
limit theorem. The minimum number of animals necessary 
was calculated to be eight per group. To evaluate possible 
differences in histomorphometric parameters (perimeter, 
area, and thickness) among the experimental groups, the 
Bartlett test for assessing data homogeneity was used 
first, followed by the ANOVA test, and then finally by 
Bonferroni’s post-hoc. The significance level for the rejection 
of the null hypothesis was fixed at 0.05 or 5% (α < 0.05).
RESULTS
Histological Analysis
No rats died during the experiment. The OSE was of 
Figure 1 - Photomicrography showing the cortical region of an ovary in 1.25 
mm extension. Letters indicate the delimitation applied to histomorphometric 
parameters. A) tracing along the superficial epithelial cells. B) tracing along 
the epithelium-stroma interface. Staining: H&E. Magnification: 400X
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simple cuboidal shape in all animals in the GPROP and 
GE0.05mg groups. However, as the estrogen dose increased, 
the lining of the epithelium thickened. This thickening was 
most obvious in the GE2mg group, where the epithelium 
was observed to be pseudo-stratified or stratified (Fig. 2). 
The percentage of rats with thickened ovarian superficial 
epithelium was 10%, 40%, and 90%, in the GE0.5mg, 
GE1mg, and GE2mg groups, respectively. The ovarian 
stroma contained a large number of interstitial cells in all 
groups receiving CEE. These cells were most numerous in 
the GE1mg and GE2mg groups (Fig. 2). The percentage of 
rats with increased interstitial cells was 70% and 100% in 
GE1mg and GE2mg, respectively. In these two groups, we 
also noticed leukocyte infiltration in several ovarian follicles, 
suggesting follicular degeneration. This phenomenon in 
G2mg (80% of the rats) was more pronounced than other 
groups . We did not observe significant differences in the 
number of ovarian follicles or in the number of corpora lutea 
among the groups under investigation. 
Histomorphometric Analysis
The animals in the GE2mg group, which received the 
largest dose of CEE (2 mg/kg), showed the largest area 
(56.63 ± 1.91 µm2 x 10-3), perimeter (23.74 ± 6.81 mm) 
and thickness (10.41 ± 0.18 µm) of OSE when compared 
Figure 2 - Photomicrography showing the cortical region of ovaries belonging to the different study groups: A) GPROP, B) GE50µg, C) GE0.5mg, D) 
GE1mg and E) GE2mg. The arrows in (D) and (E) indicate thickened superficial epithelia. H.E 260X
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to the other groups (P < 0.01). In contrast, the GE0.5mg 
and GE1mg groups showed little difference in epithelium 
thickness. Results of the morphometric analysis are shown 
in Table 1. 
DISCUSSION
Previous studies have identified some risks associated 
with HRT, including cardiovascular complications and an 
increase in hormone-dependent cancer. The balance between 
the benefits of HRT and its risks for women at the menopausal 
transition and in post-menopause remains controversial. A 
meta-analysis of research between 1966 and 2006 showed an 
increased risk of ovarian cancer among users of unopposed 
estrogen therapy compared to non-users women, with the 
relative risk of the therapy equal to 1.28 (1.18-1.40).36 Other 
studies reinforce the tumorigenic effects of estrogen on 
ovarian cancer development.37,38 This finding is worrisome and 
brings to light new questions regarding the effects of estrogen 
on OSE proliferation and cancer. , Elucidating the relationship 
between estrogen HRT and cancer potentially affects the lives 
of millions of women and may therefore be considered a 
significant public health concern. In our study, only high doses 
of estrogen (2 mg/Kg day) induced the morphometric signs of 
proliferation in the OSE. However, this dose is 20-fold higher 
than conventional HRT doses that induce similar estrogen 
concentrations in postmenopausal women.36 In a previous 
study with rats we showed that, following treatment with 
50 µg/kg of CEE, estrogen levels are close to 32 pg/ml.39, 40 
These values are similar to those found in postmenopausal 
women receiving estrogen therapy.40
Rat models, and particularly rat models of the chemical 
carcinogens 7,12-dimethylbenzanthracene (DMBA) and 
N-methyl-N-nitrosourea (MNU) are the most frequently 
used to study breast cancer chemoprevention.41-43 In intact 
females, these carcinogens also increase the incidence of 
epithelial ovarian cancer. This increase is especially strong 
in the DMBA model, where DMBA is directly applied to the 
ovarian surface epithelium and promotes neoplasia This local 
exposure to DMBA leads to epithelial cancer in 30-40% of 
the treated rats and to more frequent preneoplastic changes 
in the ovary.41-43 
However, although this model is effective, it is based 
on artificial induction of epithelial growth. Our study was 
designed to evaluate the proliferation of epithelium after 
estrogen treatment in senile rats, and this model may be 
more physiologically relevant than a model involving direct 
application of DMBA to the ovarian surface.
As female rats age, the number of ovulations and litter 
size gradually declines, until they eventually cease to cycle 
and reproduce. 44 Daily vaginal smear examinations revealed 
that, starting around 8-12 months of age or even earlier, rats 
gradually change from regular to irregular cycles, and then to 
constant estrus and finally to an anestrous state in the oldest 
rats. 44 Clemens and Meites 45 showed that gonadotropin 
levels, particularly FSH levels, are elevated during this 
anestrous phase. Therefore, senile female rats may be a good 
model because they mimic the rise in gonadotropin levels 
observed in menopausal women.
Since both gonadotropins and steroids control the 
ovary, these hormones are strong candidates as regulators 
of OSE proliferation. The fact that hormone receptors are 
present on the surface of the OSE in several species45-47 
supports the possibility that they function as regulators, 
even though interspecies variation of levels of receptor on 
the OSE suface has been reported.45,49 In general, in vivo 
studies have suggested that gonadotropins49,50 and estrogens51 
stimulate OSE cell proliferation. The histomorphologic and 
histomorphometric data in the present study seem to support 
these findings. The results of in vitro studies, in contrast, 
are contradictory. Whereas some studies have reported 
that gonadotropins and estrogens stimulate proliferation of 
OSE cells in culture,51,52 other studies have found no such 
mitogenic effect on isolated OSE cells,53,54 suggesting that 
the effects of gonadotropin and estrogens are mediated 
by the local release of other growth-promoting factors. 
Alternatively, these results may be an artifact of the in vitro 
nature of the studies. 
An interesting finding of our study is that all experimental 
groups receiving estrogen showed an increase in the number 
Table 1 - Histomorphometric analysis (mean ± standard deviation) of rat ovarian surface epithelia. Animal groupings are 
described in the Materials and Methods section












Total analyzed width per ovary (mm)a 5.01 ± 0.23 5.03 ± 0.11 4.99 ± 0.23 5.06 ± 0.16 5.02 ± 0.17
Perimeter (mm) 12.15 ± 3.11 12.09 ± 5.69 12.89 ± 7.65 16.21 ± 2.39 23.74 ± 6.81*
Thickness (µm) 5.44 ± 0.30 6.04 ± 1.36 6.48 ± 2.68 7.15 ± 0.126 10.41 ± 0.18*
Area (µm2 x 10-3) 29.11± 1.99 30.80 ± 1.96 31.91 ± 1.65 33.94 ± 2.07 56.63 ± 1.91*
n = number of animals; a Sum of all clock position fields; *P < 0.01 compared to all other groups.
386
CLINICS 2008;63:381-8Proliferation of the superficial epithelium of ovaries in senile female rats
Perniconi SE et al.
of interstitial cells, which are responsible for producing 
androgens that may increase the proliferation on OSE. 
Entrapment of ovarian superficial epithelial cells in 
inclusion cysts increases the likelihood of OSE neoplastic 
transformation, possibly as a result of the androgen-rich 
milieu of the stroma.55-56 Consistent with this androgen 
theory, women with polycystic ovary syndrome have a 
higher risk of developing ovarian cancer, which is probably 
attributable to anovulation and higher levels of circulating 
androgen. Although the androgen theory may explain the 
effect of HRT on the OSE, it is extremely difficult to prove.56 
One of the limitations of the present study is that it does not 
provide a rigorous test of this theory. Another limitation is 
that only high doses of estrogen were observed to induce the 
proliferation and therefore increase the histomorphometric 
parameters of OSE. These doses were more than 2-3 times 
higher than the doses given to women. Therefore, additional 
mechanisms and factors apart from estrogen may be involved 
in ovarian cancer, such as growth factors. It is important 
to emphasize that some women may present with high 
circulating estrogen levels following infertility treatment 
with gonadotropins or analogues, and these high levels may 
place them at greater risk of ovarian neoplasia. 57 
Estrogen is considered to be a risk factor for development 
of cancer on the ovarian superficial epithelium.38 
Furthermore, repetitive cycles of epithelial insult and repair 
during ovulation promote genomic instability, rendering 
the superficial epithelial layer vulnerable to carcinogenesis. 
In fact, increased activity of the FSH receptor on ovarian 
cells and on the epithelial surface at the site of ovulation 
induces genomic instability, increasing the likelihood that 
this cellular layer to will show aberrant proliferation.5,8 Thus, 
administration of high-dose estrogen in our experimental 
model (senile female rats) created the conditions for 
excessive proliferation of ovarian superficial epithelium, 
which may have increased the chances of developing ovarian 
cancer. However, despite promising initial results, further 
long-term studies are needed to confirm this hypothesis.
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